Skip to Content

The US just approved the use of plasma from covid-19 survivors as a treatment

The approval came days after Trump accused the “deep state” of withholding covid-19 cures.
Ahmad Ardity | Pixabay

The US has approved wide emergency use of blood plasma from covid-19 survivors as a treatment for coronavirus infection, despite limited evidence it helps.

Blood drug: The therapy, which the White House touted as a “breakthrough,” involves giving plasma from survivors to those battling the infection. It has been tried since early in the year in China, the Netherlands, and also in the US, where more than 70,000 patients have received it already as part of studies or under case-by-case medical exemptions, according to the US Food and Drug Administration.

How does it work: Blood plasma from survivors contains antibodies that can help block a virus, and studies have provided hints that transfusions can cut the chance of death, especially if given early. The FDA cited that chance in its emergency-use authorization for the treatment, calling convalescent plasma a “potential promising” treatment. The agency added, however, that plasma does not yet qualify as a new “standard of care.”

The FDA is able to approve drugs that “may be effective” for wider use during public health emergencies, even without ironclad evidence they work. The agency previously granted an emergency authorization for two malaria drugs in March, but it reversed itself in June, saying the drugs, hydroxychloroquine and chloroquine, were unlikely to be effective and caused side effects on people’s hearts.

Poorly studied: Some doctors have criticized how the treatment has been handled in the US. Because doctors have been allowed to give plasma to tens of thousands of patients outside of trials, they say, it’s been difficult to gather decisive evidence on the effects. Proof of efficacy requires controlled studies in which some patients get plasma and others get a placebo. The new authorization effectively eliminates paperwork required since April to give plasma to individual patients. Blood banks have actively recruited coronavirus survivors to donate blood.

Political pressure: Last week, the New York Times quoted government health officials who expressed concern there wasn’t enough information to back an approval. Shortly afterwards, President Donald Trump took to Twitter to accuse the FDA and the “deep state, or whoever” of slow-walking cures in order to interfere with his chances in the November general election.

Vaccine doubts: The plasma approval could foreshadow US government actions around a vaccine for covid-19, some scientists fear. The chief doctor coordinating vaccine studies in the US has said data supporting a vaccine won’t be in hand until January at the earliest, but the Financial Times reported that the administration is looking to fast-track an emergency approval of a vaccine before Election Day.  If an unsafe or ineffective vaccine goes into wide use, that will be a bigger setback than we’ll suffer if convalescent plasma proves a dud. That is because plasma is given to people who are already sick, while vaccines are given to healthy people.

Deep Dive


The first babies conceived with a sperm-injecting robot have been born

Meet the startups trying to engineer a desktop fertility machine.

Doctors have performed brain surgery on a fetus in one of the first operations of its kind

A baby girl who developed a life-threatening brain condition was successfully treated before she was born—and is now a healthy seven-week-old.

A brain implant changed her life. Then it was removed against her will.

Her case highlights why we need to enshrine neuro rights in law.

The FDA just approved rub-on gene therapy that helps “butterfly” children

Biotech companies are getting creative with how they deliver DNA fixes into people's bodies.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at with a list of newsletters you’d like to receive.